Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus

American Journal of Health-System Pharmacy

Volumn 70, Issue 15, 2013, Pages 1342-1346

  Ohler, Kirsten H ^a   Pham, Jennifer T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; ARTIFICIAL VENTILATION; COST CONTROL; FEMALE; FOLLOW UP; GESTATIONAL AGE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN INFECTION; OUTCOME ASSESSMENT; OUTPATIENT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; VIRAL BRONCHIOLITIS; AMBULATORY CARE; COMPARATIVE STUDY; DRUG ADMINISTRATION; ECONOMICS; HOSPITALIZATION; NEWBORN INTENSIVE CARE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AMBULATORY CARE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COST SAVINGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894333192     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120526     Document Type: Article

References (8)

1. Mcintosh K. Respiratory syncytial virus. In: Kliegman RM, Behrman RE, Jenson HB et al., eds. Nelson textbook of pediatrics, 18th ed. Philadelphia: Saunders; 2007:1388-90.
2. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997-1999. Pediatr Infect Dis J. 2002; 21:629-32.
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102:531-7.
4. Synagis (palivizumab) package insert. Gaithersburg, MD: MedImmune; 2006 Mar.
5. Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176:1215-24.
6. Wu SS, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004; 114:e554-6.
7. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124:1694-701.
8. Katz BZ, Sullivan C. Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit. Pediatr Infect Dis J. 2009; 28:842-4.